{"filings":[{"id":111078,"accession_number":"0001493152-26-010526","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Mangoceuticals files lawsuit seeking >$73M against Clarity Ventures; CEO options repriced to $0.45","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed lawsuit in Texas state court against Clarity Ventures seeking damages exceeding $73M for failure to deliver HIPAA-compliant ERP/eCommerce platform.","Clarity denies allegations and asserts counterclaims for unpaid invoices; company states all binding payments were made in full.","CEO Jacob Cohen's options repriced: 50,000 at $16.50, 83,333 at $4.80, 2,000,000 at $2.30 → new exercise price $0.45 per share effective March 16, 2026.","Company independently developed and deployed a new proprietary telehealth platform that does not rely on Clarity’s technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111077,"accession_number":"0001493152-26-007750","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Mangoceuticals' MGX-0024 zero respiratory mortality in 29,000-bird trial; 60% H5N1 mortality cut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three commercial field trials in India (~29,000 broilers) with MGX-0024 drinking water showed zero respiratory-related mortality vs. historical ~50%.","Controlled H5N1 challenge (ICAR-NIHSAD): 48-hr pre-treatment reduced mortality 60% (2/7 vs 5/7 deaths) and extended mean time to death to 10.71 days.","Surviving birds in H5N1 study were seronegative for H5 antibodies at day 14, suggesting early interference with infection establishment.","MGX-0024 is a GRAS-classified polyphenol/zinc formulation forming respiratory barrier; protected by US Patent 11,517,523 and international patents.","Company scaling production, pursuing regulatory discussions in US, UK, Australia, and targets commercial rollout in select markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111076,"accession_number":"0001493152-26-007468","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MangoRx's new $99/mo injectable TRT sees 336% MoM sales growth, 54% CAC drop","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Month-over-month sales of injectable TRT program increased 336% since mid-December 2025 launch.","Customer acquisition cost reduced by 54% over the same period.","Global TRT market valued at $2.11-2.2B in 2025, expected CAGR 3.9% (TBRC report).","CEO Jacob Cohen: TRT is key strategic focus; platform evolving to broader men's health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111075,"accession_number":"0001493152-26-005587","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mangoceuticals receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 4, 2026: bid price below $1.00 for 30 consecutive days.","Has 180 calendar days, until August 3, 2026, to regain compliance by closing at $1.00 or more for 10 consecutive business days.","Company will monitor closing bid price and consider available options to regain compliance.","Received notice has no immediate effect on listing or trading of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127716,"accession_number":"0001493152-25-028463","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals raises $2.5M via registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$2.5M gross proceeds from sale of 1.43M common shares at $1.295 and 500K pre-funded warrants at $1.29499.","Private placement includes warrants for up to 1.93M shares at $1.4245; exercisable for 5 years.","Net proceeds for working capital and general corporate purposes; closing expected Dec 19, 2025.","Aegis Capital Corp acts as placement agent; offering under effective shelf registration S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127715,"accession_number":"0001493152-25-028444","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Mangoceuticals partners with Cube Group for up to $100M Solana-focused digital asset treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100M Solana-focused digital asset treasury strategy launched via subsidiary Mango DAT, LLC.","Cube Group appointed as asset manager for custody and execution; founder Bartosz Lipinski leads strategy.","Minimum monthly management fee of $2,500 plus 2% annual management fee based on Solana token NAV.","Target staked yields 7-8% APY with active management targeting 8-20%.","Company may use shelf registration to sell shares via ATM or other offerings to fund Solana purchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127714,"accession_number":"0001493152-25-027009","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Mangoceuticals borrows $75K at 18% from CEO-controlled trust; matures Dec 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Dec 4, 2025, borrowed $75,000 from The Tiger Cub Trust, controlled by CEO Jacob D. Cohen.","Promissory note bears 18% annual interest, compounded monthly, maturing Dec 4, 2026 or earlier upon qualified financing.","Mandatory prepayment plus make-whole premium due within 5 business days of a qualified financing (any capital raise after note date).","Default triggers automatic increase to principal plus make-whole amount and acceleration at 18% default rate.","Related-party loan from CEO's trust; cash infusion signals near-term liquidity need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127713,"accession_number":"0001493152-25-022505","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mangoceuticals clarifies GLP-1 programs: no direct contracts with Eli Lilly or Novo Nordisk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MangoRx Direct and PeachesRx Direct can prescribe branded GLP-1s (Zepbound, Wegovy) via third-party provider.","Company has no direct contractual relationship with Eli Lilly or Novo Nordisk; access is through an independent provider.","Programs launched Nov 13, 2025 at $99/month; medication cost and fulfillment separate.","Clarification follows earlier press release that may have implied direct partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127712,"accession_number":"0001493152-25-022103","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mangoceuticals partners with Lilly and Novo Nordisk for GLP-1 access programs; $99/month membership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launches MangoRx Direct and PeachesRx Direct providing access to Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) via telehealth.","Membership fee $99/month includes unlimited virtual visits, progress tracking, lifestyle coaching; GLP-1 meds from $499/month cash-pay.","No insurance required; prescriptions fulfilled via LillyDirect Self Pay, NovoCare Pharmacy, or local pharmacies.","Company highlights White House deal lowering government GLP-1 pricing to $245/month and $50 Medicare copays from mid-2026.","CEO Jacob Cohen states program targets 42% of U.S. adults with obesity, aiming to make treatment simple and sustainable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127711,"accession_number":"0001493152-25-019941","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","5.02","9.01"],"status":"ready","headline":"Mangoceuticals leases Dallas office and separates from COO Hammer with severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters 5-year lease for 2,467 sq ft Suite 245 at 17130 Dallas Parkway; base rent $4,852/mo + operating expenses.","COO Amanda Hammer terminated effective Oct 22, 2025; receives 9 months' salary in equal installments starting Nov 1, 2025.","Indigo Capital LP converts 500 Series B shares ($500,000 stated value) into 366,667 common shares at $1.50/sh conversion price.","Platinum Point Capital converts 32 Series B shares ($35,200 stated value) into 23,466 common shares on Oct 16, 2025.","Employment agreement with Hammer terminated; no material termination penalties incurred beyond severance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144488,"accession_number":"0001493152-25-013213","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mangoceuticals grants 500k shares and 2M options to CEO; CFO and directors each receive 100k shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jacob Cohen receives 500,000 common shares as 2025 bonus and options to purchase 2,000,000 shares at $2.30.","Options vest over 18 months (500k per milestone); full acceleration on change of control or termination without cause.","CFO Eugene Johnston and directors Myers, Hamilton, D'Alessio each receive 100,000 fully vested common shares as 2025 bonuses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144487,"accession_number":"0001493152-25-012557","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals raises $1.1M via private placement of 709,677 shares at $1.55/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 709,677 restricted common shares at $1.55 per share to five accredited investors.","Gross proceeds of $1,100,000; shares carry piggyback registration rights for one year.","Offering exempt under Section 4(a)(2) and Rule 506(b) of Regulation D.","Company reserves right to reject subscriptions; no underwriting discounts paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144486,"accession_number":"0001493152-25-011557","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","1.02","2.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals terminates Diabetinol licensing deal; cancels 1M shares issued to Navy Wharf","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutually rescinded March 2025 Master Distribution Agreement for Diabetinol, effective July 30, 2025.","No material early termination penalties incurred by Mangoceuticals.","Navy Wharf agreed to cancel all 1,000,000 previously issued restricted shares as consideration.","Unrelated: warrant holder exercised 198,000 warrants at $1.50, raising $297,000 for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144485,"accession_number":"0001493152-25-011336","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals amends CEO trust note to convertible with warrants; conversion price $1.785","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended $100k promissory note from CEO's Tiger Cub Trust into convertible note; conversion price set at $1.785/share.","Issued warrants to Tiger Cub Trust to purchase 50,000 shares at $1.815/share, expiring July 21, 2028.","Removed mandatory prepayment requirement upon qualified financing.","Indigo Capital converted $500k note plus $90k interest into 393,333 shares at $1.50/share.","Sold 261,667 shares under ELOC at $1.5645/share for net proceeds of $409,367."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144484,"accession_number":"0001641172-25-018467","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Mangoceuticals subsidiary designates 1M shares of 6% Series B Convertible Preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series B Preferred has $10 stated value, 6% cumulative dividend payable quarterly.","Conversion price fixed at $1.50 per common share, with 4.999% beneficial ownership cap.","Liquidation preference of $12.50 per share plus accrued dividends; company can redeem at $12.50 after 3 years.","No voting rights except protective provisions requiring majority approval for adverse changes.","Issued by wholly-owned subsidiary Mango & Peaches Corp.; no immediate proceeds or issuance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144483,"accession_number":"0001641172-25-017879","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mangoceuticals President and Director Tony Isaac Resigns Effective June 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Antonios 'Tony' Isaac resigned as President and Board member, effective June 30, 2025.","Resignation was not due to any disagreement with the company on operations, policies, or practices.","No successor has been named as of the July 3, 2025 filing date.","CEO Jacob Cohen remains in his role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162855,"accession_number":"0001641172-25-014545","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Mangoceuticals issues ~498K shares via warrant exercises, conversion, and ELOC draw","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cashless warrant exercises: Abri Advisors (93,731 shares) and Clover Crest (131,250 shares) on June 2.","Indigo Capital cash-exercised warrants for 100,000 shares at $1.50 each on June 9, raising $150,000.","Series B Preferred holder converted 100 shares into 73,333 common shares on June 5.","ELOC draw of 100,000 shares at $1.9319 on June 5, netting $193,190 from Platinum Point Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162854,"accession_number":"0001641172-25-012917","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals raises $116K in unit offering, converts $500K note into convertible debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 70,454 units at $1.65 each for $116,249, each unit includes 1 share and half warrant to buy 1 share at $3.00.","Amended $500K promissory note with Indigo Capital LP into convertible note at $1.50/share, removing mandatory prepayment clause.","Granted Indigo Capital warrants to purchase 275,482 shares at $1.815/share, expiring May 27, 2028.","Issued 120,000 restricted shares to Levo Healthcare for digital marketing services, vesting 10,000 shares/month over 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162853,"accession_number":"0001641172-25-012336","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["1.01","1.02","2.01","9.01"],"status":"ready","headline":"Mangoceuticals rescinds IP purchase and consulting pacts, cancels 1.65M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 22, 2025, entered rescission agreements with ArcStone, Smokeless, and Strategem.","ArcStone retains 50,000 shares; remaining 50,000 cancelled for consulting services.","Smokeless Technology cancels all 1,600,000 shares issued for oral-pouch IP acquisition.","Strategem Solutions waives issuance of 120,000 shares and forfeits monthly cash fees.","No material termination penalties except the 50,000 ArcStone shares retained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162852,"accession_number":"0001641172-25-008878","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Mangoceuticals settles lawsuit with 62,500 shares, gets $100k loan from CEO trust at 18%","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Entered settlement with 1800 Diagonal Lending, issuing 62,500 restricted shares to dismiss lawsuit with prejudice (May 5, 2025).","Borrowed $100,000 from The Tiger Cub Trust (CEO-controlled) via 18% promissory note maturing May 2, 2026.","Two Series B Preferred conversions: 100 shares for 73,333 common (Apr 28) and 300 shares for 220,000 common (May 1).","Outstanding common shares now 11,034,023 after settlement and conversion issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162851,"accession_number":"0001641172-25-006122","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Mangoceuticals acquires Smokeless Technology IP, enters oral pouch market with 1.6M shares and royalty","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired IP from Smokeless Technology Corp. for 1,600,000 restricted shares of MGRX common stock and 10% royalty on gross pouch product sales.","Appointed Tim Corkum, former Philip Morris and JUUL executive, as President of new pouch subsidiary via Consulting Agreement with Strategem Solutions for 120,000 shares and $12,500/month.","CEO Jacob Cohen received amended employment: base salary raised to $420,000, bonus of 3,192,906 shares of M&P subsidiary stock, and increased allowances.","Pouch market projected to exceed $37 billion by 2032; Mangoceuticals plans to leverage distribution and telemedicine platform for new product lines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162850,"accession_number":"0001641172-25-005263","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Mangoceuticals sells $100K Series B preferred, borrows $500K at 18% from Indigo Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 100 shares of Series B Convertible Preferred at $100K; stated value $1,100/share, convertible at $1.50 into up to 73,333 common shares.","Purchaser granted right to participate in any subsequent financing for 18 months from closing.","Borrowed $500K from Indigo Capital LP via Promissory Note at 18% annual interest compounded monthly, maturing April 15, 2026.","Prepayment premium equals interest to stated maturity; mandatory prepayment on qualified financing; default triggers acceleration and additional interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162849,"accession_number":"0001641172-25-003881","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mangoceuticals issues 335,000 fully-vested shares as 2025 discretionary bonus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jacob Cohen received 200,000 shares; President Antonios Isaac received 60,000 shares.","Three directors (Myers, Hamilton, D'Alessio) each received 25,000 shares.","Shares issued under Second Amended and Restated 2022 Equity Plan on April 10, 2025.","Awards are fully vested and earned for services rendered during 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162848,"accession_number":"0001641172-25-003245","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Mangoceuticals issues 590,000 common shares on conversions of preferred stock and debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["March 28: 350 Series B Convertible Preferred shares (stated value $385,000) converted into 256,666 common shares at $1.50/share.","April 2: MAAB Global Ltd. converted $500,000 of debt into 333,333 common shares at $1.50/share.","Issuances exempt under Section 3(a)(9) as exchanges with existing holders; no commission paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162847,"accession_number":"0001493152-25-011197","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Mangoceuticals reports Series B Preferred conversions into 287,467 common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three holders converted 392 Series B Preferred shares (aggregate stated value $431,200) at $1.50/share.","Total common shares issued: 287,467, diluting existing shareholders per preferred terms.","Exemption claimed under Securities Act Section 3(a)(9) for exchange with existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180803,"accession_number":"0001493152-25-011191","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Series B Preferred holders convert ~609K shares of common stock, aggregate stated value $913K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On March 25, 2025: 116 shares (stated value $127,600) converted to 85,067 common shares.","Same day: 350 shares ($385,000) to 256,667 common; 146 shares ($160,600) to 107,067 common.","On March 26, 2025: 218 shares ($239,800) converted to 159,867 common shares.","All conversions at $1.50 per share; no commissions paid, exempt under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180802,"accession_number":"0001641172-25-000525","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Mangoceuticals secures exclusive US/Canada rights to Diabetinol®; 1M shares and royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive rights to Diabetinol® in US & Canada; nutraceutical for blood glucose/HbA1c management.","Consideration: 1M restricted shares (~16% dilution) plus 10% net sales revenue.","Term perpetual; if <$1.5M sales by Dec 2026, rights become non-exclusive; can extend 12 mo with $5M payment.","Raised $200k via sale of 80k shares at $2.50/share to accredited investor.","Clinical study: 14.3% reached HbA1c targets (vs 0% placebo); 83.3% reached SBP goals (vs 60%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180801,"accession_number":"0001493152-25-010875","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["3.02","5.03","3.03","5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Series B conversion price cut to $1.50 and 2022 equity plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series B Preferred conversion price reduced to $1.50 (from $2.25); floor price removed; dividend rights eliminated.","2022 Equity Incentive Plan amended: share reserve 10M shares, evergreen up to 2M shares/yr, max 26M shares.","Stockholders approved issuance of Mango & Peaches subsidiary shares to CEO Jacob Cohen under Nasdaq Rule 5635.","All four proposals approved at March 17, 2025 special meeting; Proposal 1 received 98.8% common and 100% Series B votes.","Designation Amendment filed with Texas Secretary of State on March 17, 2025, effective upon stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180800,"accession_number":"0001493152-25-007597","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals enters advisory consulting agreement and receives $120K from warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 200,000 restricted shares to 6330 Investment & Consulting for 12-month strategic advisory services.","Received $120,000 aggregate exercise price for 80,000 shares from a warrant holder at $1.50 per share.","Consultant will provide introductions for strategic partners and M&A opportunities; estimated 10 hours/week.","Shares issued under Section 4(a)(2) exemption; no public offering or underwriting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180799,"accession_number":"0001493152-25-006139","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Amends $20M patent deal to credit R&D costs; raises $710K via stock sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amends Patent Purchase Agreement; cash payments reduced to $306K from $373K as of Dec 31, 2024.","Issued 155,555 shares at $2.25/share for $350K to accredited investor in private placement.","Received $210K from exercise of 140,000 warrants at $1.50/share on Feb 10.","Received $150K from exercise of 100,000 warrants at $1.50/share on Feb 11.","Series B Preferred converted 216 shares (stated value $237,600) into 105,600 common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180798,"accession_number":"0001493152-25-006040","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mangoceuticals announces study on avian flu prevention in poultry using water-based antiviral solution","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Engaged Vipragen Biosciences for efficacy studies on H5N1 prevention via drinking water solution.","Phase I animal studies showed significant reduction in lung viral load; Phase II ongoing.","Solution uses GRAS ingredients; aims to offer non-pharmaceutical preventive tool.","Avian flu outbreak led to culling of >148M birds in U.S. since 2022; egg prices hit $4.15/dozen Dec 2024.","Global poultry market projected at $375.41B by 2030; company to share final study results upon completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180797,"accession_number":"0001493152-25-005457","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Mangoceuticals sells 70k shares at $1.50, expands COO role, grants subsidiary control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 70,000 restricted shares to accredited investor for $105,000 at $1.50/share via exempt private placement.","Expanded COO Amanda Hammer's role to include COO of subsidiary M&P; salary raised to $180,000/year.","Company agreed to issue Jacob Cohen 1.7M common shares and super-voting preferred of M&P for 51% voting control.","Hammer received $15,000 cash bonus within 30 days of amendment effective Feb 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180796,"accession_number":"0001493152-25-004501","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals converts $500k debt to equity at $1.50/share; licenses Dermytol skin care for 650k shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered First Amendment with MAAB Global to convert $500,000 debt into up to 333,334 shares at $1.50/share.","Signed Master Distribution Agreement with Propre Energie for Dermytol® formulations; pays 650,000 restricted shares and 1% gross sales revenue.","Assigned rights under two Epiq Scripts agreements to subsidiary M&P; CEO Jacob Cohen is 51% owner of Epiq Scripts.","Entered LT Global Practice Management Service Agreement (CEO's wife's company) for virtual professionals at $1,800-$3,500 each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180795,"accession_number":"0001493152-25-003054","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["1.01","5.02","3.02","8.01","9.01"],"status":"ready","headline":"Mangoceuticals converts $150K note into 100K shares; appoints Antonios Isaac as President & Director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Debt conversion with Mill End Capital: $150K promissory note converted to 100K restricted common shares at $1.50/share.","Antonios Isaac appointed as Director and President; enters 12-month consulting agreement at $10K/month.","Final 250 shares of Series B Preferred Stock sold for $250K, completing Fourth Closing under 2024 SPA.","Conversion of note triggers anti-dilution repricing: all outstanding warrants and Series B conversion price adjusted to $1.50/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180794,"accession_number":"0001493152-25-002389","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Mangoceuticals subsidiary creates Series A Preferred Stock granting CEO 51% voting control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series A Preferred Stock of M&P subsidiary gives holders 51% of total vote on all shareholder matters.","100 shares designated; expected to be issued to CEO Jacob Cohen under his employment agreement.","M&P cannot amend charter or issue more shares without 66-2/3% approval of Series A holders.","Designation filed Jan 9, 2025, effective same date; filed with Texas SOS on Jan 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180793,"accession_number":"0001493152-25-001401","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals raises $900k via Series B Preferred and warrants for 1.188M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed four SPAs from Dec 31, 2024 through Jan 6, 2025, selling 900 shares of Series B Preferred at $1,000 each for $900k total.","Issued warrants to purchase up to 1,188,000 shares, exercisable at 105% of 10-day VWAP (range $2.57–$2.61), 5-year term.","Warrants exercisable after 180 days; include dilutive issuance price adjustments and cashless exercise if registration not effective.","Series B Preferred convertible at $1,100 stated value, floor price $2.25; 440,000 common shares issuable on full conversion.","Offering of 1,250 Series B Preferred shares closed; securities issued under Section 4(a)(2)/Reg D, no public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197660,"accession_number":"0001493152-24-052111","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals raises up to $1.25M via Series B Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 350 shares of Series B Preferred for $350K and warrants for 462K shares at $2.57-$2.71 exercise price.","Anticipates selling additional $900K of Series B Preferred and 1.188M warrants on similar terms.","Warrants exercisable after 180 days, 5-year term; conversion of Preferred limited by $2.25 floor price.","Purchasers granted 18-month participation right in future financings up to their subscription amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197659,"accession_number":"0001493152-24-050830","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","5.02","2.01","3.02","3.03","5.01","8.01","9.01"],"status":"ready","headline":"Mangoceuticals acquires mushroom patent for 515k shares; CEO Cohen secures 75.5% voting control of subsidiary M&P","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired mushroom patent WO 2023/086647 from Greenfield Investments for 515,000 restricted shares of common stock.","Contributed substantially all assets (MangoRx Mexico and UK) to new subsidiary Mango & Peaches Corp.","CEO Jacob Cohen received 1.7M common shares (25.4%) and Series A preferred with 51% voting power, totaling 75.5% voting control of M&P.","CEO base salary raised to $360k/year; severance increased to 3x salary plus target bonus; term extended to Dec 2027.","Granted Greenfield a co-exclusive license to patents for 10% royalty on gross sales starting Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197658,"accession_number":"0001493152-24-049133","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Mangoceuticals enters service agreement with Greentree, issues 40k shares and draws $159,950 from ELOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Service agreement with Greentree Financial Group for compliance filings, accounting advice, and tax return preparation; fee of $40,000 cash plus 40,000 restricted common shares.","CFO Eugene M. Johnston serves as Audit Manager for Greentree, creating a related-party transaction.","Term through October 15, 2025; early termination by Company triggers immediate payment of full cash fee.","Separate ELOC draw: 75,000 shares sold to Platinum Point Capital on December 4, 2024, netting $159,950.","All shares issued are unregistered, exempt under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197657,"accession_number":"0001493152-24-044828","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mangoceuticals enters CFO consulting agreement; $4k/month, 25k shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement with CFO Eugene Johnston effective Oct 1, 2024 for 12 months.","Cash compensation: $4,000 per month.","Equity: 25,000 shares of common stock under 2022 Equity Incentive Plan, vested on execution.","Agreement includes non-solicitation covenants and standard confidentiality.","Johnston continues as CFO; no change in leadership role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197656,"accession_number":"0001493152-24-043134","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mangoceuticals regains Nasdaq minimum bid price compliance after reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Oct 30, 2024 confirming full compliance with Minimum Bid Price Requirement.","1-for-15 reverse stock split effective Oct 16, 2024 helped meet the $1.00 bid price threshold.","Nasdaq determined closing bid price was at or above $1.00 for 10 consecutive business days.","Compliance matter is now closed, removing delisting risk from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197655,"accession_number":"0001493152-24-042546","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Mangoceuticals issues 33,333 shares under ELOC and converts 200 Series B shares into 93,299 common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 33,333 shares at $2.36 each for net proceeds of $78,787 under the $25M ELOC with Platinum Point Capital.","Converted 200 Series B Preferred shares into 93,299 common shares at $2.358/share, value $220,000.","Both issuances exempt from registration under Securities Act (Section 4(a)(2)/Rule 506 and Section 3(a)(9)).","Resale of shares under ELOC and conversion are covered by effective registration statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197654,"accession_number":"0001493152-24-041885","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"MangoRx Board initiates strategic alternatives review to maximize shareholder value","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Formalized $150K promissory note with CEO's entity Cohen Enterprises at 8% interest, due Jan 2, 2025.","Board formed strategy committee to explore mergers, acquisitions, divestitures, and business combinations.","Process is in parallel with current operations; no timeline or assurance of any transaction.","Company previously disclosed $50K loan from March 2024 and $100K loan from April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197653,"accession_number":"0001493152-24-041802","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MangoRx faces Eli Lilly lawsuit over alleged copying of weight-loss drugs Zepbound/Mounjaro","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Eli Lilly filed a lawsuit claiming MangoRx improperly copied its weight-loss medicines Zepbound and Mounjaro.","MangoRx strongly refutes all claims regarding the sale of compounded tirzepatide and will vigorously defend.","MangoRx provides access to compounded tirzepatide via its telemedicine platform for men's health and wellness.","No financial details or specific damages claimed are disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197652,"accession_number":"0001493152-24-040955","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Mangoceuticals announces 1-for-15 reverse stock split to meet Nasdaq $1 bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:15 ratio effective October 16, 2024 at 12:01 a.m. ET.","Outstanding shares reduced from ~35.5M to ~2.4M (subject to fractional rounding).","Split aimed at regaining Nasdaq minimum $1.00 bid price; compliance deadline Oct 28, 2024.","Trading symbol MGRX unchanged; proportional adjustments made to options and warrants.","Authority granted by stockholders in March 2024; final ratio set by Board on Oct 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197651,"accession_number":"0001493152-24-039300","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MangoRx launches oral Tirzepatide weight loss tablet 'TRIM' at $399/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TRIM is a compounded oral dissolvable Tirzepatide tablet priced at $399 per month.","Tirzepatide is a dual GIP/GLP-1 receptor agonist; clinical trials showed up to 20% weight loss in 72 weeks.","TRIM complements existing oral Semaglutide product (SLIM), offering two GLP-1 options.","Global GLP-1 market projected to grow from $49.3B (2024) to $157.5B by 2035 per Roots Analysis.","Available by prescription via MangoRx telemedicine platform; targets non-injectable weight loss demand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197650,"accession_number":"0001493152-24-039223","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Mangoceuticals issues shares and warrants to consultants, draws $521K from ELOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 150k shares to Veritas Consulting for $43,155 value; $7.5k/month cash for 3-month consulting.","Issued 195k shares to Levo Healthcare for $56,102 value; warrants for up to 300k shares upon customer milestones.","Issued 650k shares to Luca Consulting for $175,500 value; $5k monthly cash for 6-month consulting.","Drew $521k from ELOC via 2M shares at $0.26/share on Oct 1, 2024.","Platinum Point converted 330 Series B Preferred shares into ~1.72M common shares in Sept/Oct."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197649,"accession_number":"0001493152-24-038933","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MangoRx launches oral Semaglutide weight-loss treatment 'Slim' at $299/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched oral Semaglutide ODT compounded with Vitamin B6, branded 'Slim', on MangoRx.com.","Priced at $299 per month; available via MangoRx telemedicine platform with physician review.","Targets global GLP-1 market projected to grow from $49.3B in 2024 to $157.5B by 2035 (Roots Analysis).","CEO Jacob Cohen cites growing GLP-1 demand; product aims to boost revenue and market share.","Oral dissolvable tablet format offers needle-free alternative to traditional injections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213883,"accession_number":"0001493152-24-038544","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Mangoceuticals sells 250 Series B Preferred shares for $250,000 in fourth closing under SPA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 250 Series B Preferred shares to institutional accredited investor for $250,000; effective price at 10% discount to $1,100 stated value.","Total 750 of 1,000 possible Series B shares sold to date; 250 remain available for future sale.","Full conversion at $0.15 floor price yields 1,833,333 common shares; shareholder approval obtained for >19.99% issuance.","Issuance exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213882,"accession_number":"0001493152-24-033739","cik":1938046,"company_name":"MANGOCEUTICALS, INC.","ticker":"MGRX","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"Mangoceuticals sells 500 Series B Convertible Preferred shares for $500k; CEO car allowance raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 500 Series B Preferred shares at 10% discount to $1,100 stated value, raising $500k from institutional investor.","Full conversion could yield up to 3,666,667 common shares at a $0.15 floor price.","Board raised CEO Jacob Cohen's monthly car allowance from $1,500 to $2,500 effective August 22, 2024.","Issuance exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8812037.624167843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-23T23:59:59+00:00|213882"}